ReviewJournal of assisted reproduction and genetics2020
An update on stem cell therapy for Asherman syndrome.
Review in Journal of assisted reproduction and genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 89 citations in OpenAlex.
- Autologous platelet-rich plasma treatment for moderate-severe Asherman syndrome: the first experience.Journal of assisted reproduction and genetics · 2021Trial
- Therapeutic potential of stem cells in addressing female infertility: recent progress and prospective developments.Frontiers in medicine · 2026Review
- Biomaterials for Reproductive Restoration: Translating Engineering Innovations.Biomaterials research · 2026Review
- The Contribution of CD26-Negative Fibroblasts to Endometrial Scarring.Biomolecules · 2025Article
- Regenerating the uterus: translational advances in endometrial bioengineering and immunotherapeutics.Seminars in immunopathology · 2025Review
- Microencapsulated 3D culture of human umbilical cord-derived mesenchymal stem cells enhances their therapeutic effect on intrauterine adhesion.Stem cells translational medicine · 2025Article
- Novel therapeutic strategies for Asherman's syndrome: Endometrial regeneration using menstrual blood-derived stem cells.Regenerative therapy · 2025Review
- Collagen Scaffold Augments the Therapeutic Effect of Human Umbilical Cord Mesenchymal Stem Cells in a Rat Model of Intrauterine Adhesion.International journal of stem cells · 2025Article
- The application of tissue engineering strategies for uterine regeneration.Materials today. Bio · 2025Review
- Defining optimal electrospun membranes to enhance biological activities of human endometrial MSCs.Frontiers in bioengineering and biotechnology · 2025Article
- Application of biomaterials in mesenchymal stem cell based endometrial reconstruction: current status and challenges.Frontiers in bioengineering and biotechnology · 2025Review
- Development and functional evaluation of recombinant type III collagen intrauterine implant gel.Regenerative biomaterials · 2025Article
- The Endometrial Stem/Progenitor Cells and Their Niches.Stem cell reviews and reports · 2024Review
- Secretion of WNT7A by UC-MSCs assist in promoting the endometrial epithelial regeneration.iScience · 2024Article
- Injectable "Homing-Like" Bioactive Short-Fibers for Endometrial Repair and Efficient Live Births.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Article
- Developing and validating a prediction model of live birth in patients with moderate-to-severe intrauterine adhesions: a new approach with endometrial morphology measurement by 3D transvaginal ultrasound.Quantitative imaging in medicine and surgery · 2024Article
- Perspectives in adhesion prevention in gynaecological surgery.Facts, views & vision in ObGyn · 2023Article
- Cyclical endometrial repair and regeneration: Molecular mechanisms, diseases, and therapeutic interventions.MedComm · 2023Review
- Stem cells implanted with nanofibrous mats for injured endometrial regeneration and immune-microenvironment remodeling.Materials today. Bio · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current treatment for Asherman syndrome is limited and not very effective. The aim of this review is to summarize the most recent evidence for stem cells in the treatment of Asherman syndrome. The advent of stem cell therapy has propagated experimentation on mice and humans as a novel treatment. The consensus is that the regenerative capacity of stem cells has demonstrated improved outcomes in terms of fertility and fibrosis in both mice and humans with Asherman syndrome. Stem cells have effects on tissue repair by homing to the injured site, recruiting other cells by secreting chemokines, modulating the immune system, differentiating into other types of cells, proliferating into daughter cells, and potentially having antimicrobial activity. The studies reviewed examine different origins and administration modalities of stem cells. In preclinical models, therapeutic systemic injection of stem cells is more effective than direct intrauterine injection in regenerating the endometrium. In conjunction, bone marrow-derived stem cells have a stronger effect on uterine regeneration than uterine-derived stem cells, likely due to their broader differentiation potency. Clinical trials have demonstrated the initial safety and effectiveness profiles of menstrual, bone marrow, umbilical cord, and adipose tissue-derived stem cells in resumption of menstruation, fertility outcomes, and endometrial regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.